Introduction {#section1-1533033818806498}
============

High-grade gliomas (HGGs) are the most frequent brain tumors in adults, with an annual incidence of 6 cases per one hundred thousand worldwide.^[@bibr1-1533033818806498]^

The main current recommendation for treatment is full microsurgical resection for all patients. If this is not feasible, a stereotactic biopsy should be carried out. After surgery, patients should receive radiotherapy and chemotherapy based on histology and molecular analysis.^[@bibr2-1533033818806498][@bibr3-1533033818806498][@bibr4-1533033818806498][@bibr5-1533033818806498]-[@bibr6-1533033818806498]^

Unfortunately, these malignant brain tumors are radioresistant and chemoresistant and have a very poor prognosis. Also, the risk of relapse and progression is inevitable.^[@bibr2-1533033818806498],[@bibr7-1533033818806498]^

The management of tumor recurrence is not standardized and may be difficult. It requires an individual evaluation based on age, performance status, histology, extent of the initial resection, type of response to initial therapy, time since diagnosis, and recurrence size.^[@bibr8-1533033818806498],[@bibr9-1533033818806498]^

The treatment of HGG recurrences and progressions must be evaluated in multidisciplinary tumor board and a surgical treatment must be systematically discussed. The other possible treatments include radiotherapy, chemotherapy (temozolomide \[TMZ\]; fotemustine; lomustine, procarbazine, and vincristine \[PCV\], etc), targeted therapies (bevacizumab), or novel agents which are proposed in the framework of clinical trials.^[@bibr10-1533033818806498]^

For the treatment of HGG recurrence by radiotherapy, many approaches have been studied, including brachytherapy, single-fraction radiosurgery, hypofractionated stereotactic radiotherapy (HFSRT), or conventional fractionated radiotherapy^[@bibr10-1533033818806498][@bibr11-1533033818806498][@bibr12-1533033818806498][@bibr13-1533033818806498][@bibr14-1533033818806498][@bibr15-1533033818806498][@bibr16-1533033818806498][@bibr17-1533033818806498]-[@bibr18-1533033818806498]^; however, none of these treatments demonstrated significant improvement in a phase III study.

Nevertheless, stereotactic radiotherapy is an interesting approach because it is minimally invasive, ambulatory, short-lasting, and well tolerated.^[@bibr17-1533033818806498]^ Several studies^[@bibr19-1533033818806498][@bibr20-1533033818806498][@bibr21-1533033818806498][@bibr22-1533033818806498][@bibr23-1533033818806498][@bibr24-1533033818806498][@bibr25-1533033818806498][@bibr26-1533033818806498][@bibr27-1533033818806498][@bibr28-1533033818806498][@bibr29-1533033818806498][@bibr30-1533033818806498][@bibr31-1533033818806498][@bibr32-1533033818806498][@bibr33-1533033818806498][@bibr34-1533033818806498][@bibr35-1533033818806498][@bibr36-1533033818806498][@bibr37-1533033818806498][@bibr38-1533033818806498][@bibr39-1533033818806498][@bibr40-1533033818806498][@bibr41-1533033818806498][@bibr42-1533033818806498][@bibr43-1533033818806498][@bibr44-1533033818806498][@bibr45-1533033818806498]-[@bibr46-1533033818806498]^ have reported the feasibility of HFSRT as it shows potential efficacy and acceptable toxicity for the treatment of recurrent HGGs.

The aim of this study was to evaluate the efficacy of and safety to HFSRT as a salvage treatment for patients suffering from HGG relapse in our cancer center and to compare these results with the literature.

Material and Methods {#section2-1533033818806498}
====================

Between March 2012 and March 2017, 32 consecutive patients with recurrent HGG received HFSRT at the Department of Radiation Oncology of Georges-François Leclerc Cancer Center in Dijon, Burgundy, France.

Eligibility Criteria {#section3-1533033818806498}
--------------------

The study was approved by our institutional review board. The study included patients with HGG diagnosed on the initial pathological analysis and patients who presented a transformation from a low-grade lesion into a high-grade lesion during follow-up (contrast-enhanced magnetic resonance imaging \[MRI\]). All patients underwent neurosurgery followed by fractionated brain irradiation with a standard dose (54 or 60 Gy) with or without chemotherapy. Tumor progression or recurrence was assessed by MRI scans during follow-up or when the neurological condition of patients deteriorated. The decision to treat the relapse with HFSRT was confirmed in a multidisciplinary neuro-oncology tumor board.

Treatment Planning {#section4-1533033818806498}
------------------

Computed tomography (CT) simulations with slice thickness of 1.25 mm were performed, using a LightSpeed RT16 Vision (GE Health Care, Milwaukee, Wisconsin). During the planning CT, patients were fitted with a thermoplastic mask system dedicated to stereotactic treatment to ensure immobilization and reproducibility. Patients were treated with a stereotactic approach, using intensity-modulated radiation therapy (5-7 static fields) or volumetric-modulated arc therapy (1-4 arcs) technology with a Varian linear accelerator (Varian Medical Systems, Palo Alto, California): Trilogy with SonArray patient positioning system and Bite-Block system. Since 2015, a NovalisTx with BrainLAB and Exatrac systems (BrainLAB, Munich, Germany) has been used.

The dose prescribed for reirradiation was based on the localization of prior radiation therapy, the site of the lesion, and its proximity to organs at risk or the recurrence volume.

A total dose of 30 Gy in 6 fractions with 2 or 3 fractions per week was delivered, corresponding to a biologically effective dose (BED) of 80 Gy (α/β = 3) and 45 Gy (α/β = 10). For a reirradiation in the initial planning target volume (PTV), a cumulative BED with the first course (60 Gy in 30 fractions) corresponded to 180 Gy (α/β = 3) and 117 Gy (α/β = 10). One patient, who had 2 lesions, was treated with 27 Gy in 3 fractions with 3 fractions per week on each lesion (BED = 108 Gy; α/β = 3-51.3 Gy; α/β = 10 and a cumulative BED of 208 Gy \[α/β = 3\] or 123.3 Gy \[α/β = 10\]). The treatment plans were normalized to 100% at the isocenter and prescribed to the 80% isodose line. Treatment was planned using the fusion of CT and MRI images. The clinical target volume (CTV) corresponded to the gross target volume obtained using contrast-enhanced T1-weighted MRI, edema (T2 FLAIR) was not included in the CTV. This volume was expanded by margins of 2 or 3 mm to generate the PTV, except for one of the first patients treated with a 5 mm PTV. The medullary canal, brainstem, whole brain, normal brain (whole brain minus PTV minus cerebellum), anterior and posterior chambers of eyeballs, chiasma, optical nerves, and cochlea, defined as organ at risks, were delineated.

The Eclipse Treatment Planning System (version 11) was used with Analytical Anisotropic Algorithm model to plan dosimetry. A Patient-Specific Quality Assurance has been performed before start of treatment.

Concomitant Drugs {#section5-1533033818806498}
-----------------

Most patients (31; 96.9%) were treated without chemotherapy. One (3.1%) patient received concomitant bevacizumab (10 mg/kg, every 2 weeks).

Follow-Up {#section6-1533033818806498}
---------

Clinical and radiological data for follow-up were collected at the first medical consultation after HFSRT (for adjuvant chemotherapy or systematic follow-up), and after each medical consultation with a radiological (MRI) evaluation and at each change of therapeutic line. This radiological evaluation has been performed every 3 months after reirradiation.

The primary endpoint of this study was survival. Overall survival (OS) was calculated from the end of the HFSRT. Progression-free survival (PFS) was calculated from the end of HSFRT until tumor progression or death (by any cause). Tumor progression was defined according to response assessment in neuro-oncology criteria. The secondary endpoint of this study was toxicity, which was classified according to the common terminology criteria for adverse events v 4.03.

Statistical Analysis {#section7-1533033818806498}
--------------------

Categorical variables are presented as percentages and were compared using the χ^2^ or Fisher test. Continuous variables are described as means (with standard deviations) and medians (with ranges) and were compared using the Student or Wilcoxon test in case of non-normal distribution. The median survival time was estimated using the reverse Kaplan-Meier method. Survival probabilities were estimated using the Kaplan-Meier method and the log-rank test was used to compare survival curves. Hazard ratios and their 95% confidence interval for univariate and multivariate analysis of OS were estimated using a Cox proportional hazards regression model. Correlations between covariables were tested for eligible variables. To prevent collinearity, when 2 variables were significantly correlated, one variable was retained according to its clinical relevance or to the value of the likelihood ratio. Statistical analyses were performed using SAS 9.3 software. All tests were 2 sided, and *P* values were considered significant when less than .05.

Results {#section8-1533033818806498}
=======

Patients {#section9-1533033818806498}
--------

The characteristics of 32 patients are resumed in [Table 1](#table1-1533033818806498){ref-type="table"}. The median age at HGG diagnosis was 57.5 (29-76) years. There were 20 (62.5%) men and 12 (37.5%) women. At the moment of recurrence, all patients presented an HGG: 18 (56.25%) glioblastoma (GBM) and 14 (43.75%) grade III gliomas. According to the 2007 World Health Organization classification in force at the time of diagnosis, there were distributed as follows: 9 (28.13%) oligodendrogliomas, 3 (9.38%) astrocytomas, and 2 (6.25%) oligoastrocytomas. Seven patients (21.88%) presented a transformation from low grade to high grade, whose 2 patients with a histological confirmation.

###### 

Patients and Initial Tumor Characteristics.

![](10.1177_1533033818806498-table1)

  ----------------------------------------------- ------------------
  Patients                                        N = 32
   Women                                          12 (37.5%)
   Men                                            20 (62.5%)
   Median age at HGG diagnosis                    57.5 (29.0-76.0)
   Pathology                                      
    Oligodendroglioma                             9 (28.1%)
    Oligoastrocytoma                              2 (6.3%)
    Astrocytoma                                   3 (9.4%)
    Glioblastoma                                  18 (56.3%)
   Methylation MGMT                               
    Yes                                           7 (21.9%)
    No                                            6 (18.8%)
    Unknown                                       19 (59.4%)
   Mutation IDH1                                  
    Yes                                           1 (3.1%)
    No                                            5 (15.6%)
    Unknown                                       26 (81.3%)
   1p19q codeletion                               
    No                                            4 (12.5%)
    Unknown                                       28 (87.5%)
  Treatment characteristics                       
   Extent of surgery                              
    Gross total resection                         6 (19.4%)
    Subtotal resection                            17 (54.8%)
    Stereotactic biopsy                           8 (25.8%)
    Unknown                                       1 (3.1%)
   Salvage surgery prior to initial irradiation   
    Subtotal resection                            2 (6.3%)
    Unknown                                       1 (3.1%)
    No                                            29 (90.6%)
   Chemotherapy prior to initial irradiation      8 (25%)
   Radiochemotherapy                              
    Radiotherapy alone                            6 (18.75%)
    Radio chemotherapy                            26 (81.25%)
   Dose                                           
    60 Gy/30 fr                                   30 (93.75%)
    54 Gy/27 fr                                   2 (6.25%)
   Concomitant chemotherapy                       
    TMZ                                           22 (84.6%)
    TMZ + bevacizumab                             4 (15.4%)
  ----------------------------------------------- ------------------

Abbreviations: fr, fractions; HGG, high-grade glioma; MGMT, O^[@bibr6-1533033818806498]^-methylguanin-DNA-methyltransferase; TMZ, temozolomide.

O^6^-methylguanin-DNA-methyltransferase status was known for 13 patients (40.7%), of whom 7 (21.9%) showed hypermethylation. An IDH1 mutation was identified for 1 patient (3.1%) and was negative for 5 (15.6%) others. 1p19q codeletion status was known for 4 patients (12.5%) and was negative.

Primary Treatment {#section10-1533033818806498}
-----------------

All patients had undergone at least one neurosurgical intervention. At the initial diagnosis, gross total resection was performed in 6 patients (18.75%), subtotal resection was performed in 17 patients (53.13%), a stereotactic biopsy was done in 8 patients (25%), and the surgical status was unknown for 1 patient (3.1%). Three patients (9.38%) underwent a second surgery prior to the radiation therapy.

All of the patients received a full course of radiation therapy with a median dose of 60 Gy (54-60) in conventional fractionation; 2 patients (6.25%) received 54 Gy in 27 fractions and the other (93.75%) patients 60 Gy in 30 fractions. Six patients (18.75%) had radiotherapy alone and 26 (81.25%) received concomitant chemotherapy according to the Stupp protocol.^[@bibr2-1533033818806498]^ Four patients also had concomitant bevacizumab as part of a protocol.

Disease Evolution {#section11-1533033818806498}
-----------------

The median time between HGG diagnosis and the first recurrence or progression was 1.3 (0-8.4) years and time between the initial radiation therapy and the first recurrence was 1.2 (0.08-11.3) years. The median number of recurrences prior to the HFSRT was 2 (1-5), and 18 patients (56.25%) received 1 to 3 systemic salvage therapies with various agents such as PCV, TMZ, bevacizumab, lomustine, and fotemustine.

Seven patients (21.88%) had salvage neurosurgery (4 with macroscopic resection and 3 with subtotal surgery), 1 patient (3.1%) had 2 surgeries: the first macroscopic and the second subtotal.

Recurrence at the Time of HSFRT {#section12-1533033818806498}
-------------------------------

At the time of the HSFRT, the median age was 61.5 (33-77) years. Ten (31.3%), 14 (43.8%), and 8 (25%) patients had an Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2, respectively. The recursive partitioning analysis status was III for 7 (21.9%), IV for 12 (37.5%), V for 11 (34.4%), and VI for 2 (6.3%) patients.

The median time between the HGG diagnosis and HFSRT was 2 (0.6-13.4) years while the time between the primary radiotherapy and reirradiation was 1.9 (0.5-13.2) years.

Two patients (6.25%) presented bifocal recurrence at the time of the HSFRT. The characteristics of the 34 lesions treated with HFSRT are resumed in [Table 2](#table2-1533033818806498){ref-type="table"}.

###### 

Patients, Recurrent Tumor, and HFSRT Characteristics.

![](10.1177_1533033818806498-table2)

  --------------------------------------------------------- ------------------------------------------
  Patients                                                  N = 32
   Median age at stereotactic radiotherapy \[min-max\]      61.5 \[33.0-77.0\]
   ECOG status: 0/1/2                                       10 (31.3%)/14 (43.8%)/8 (25.0%)
   RPA status: III/IV/V/VI                                  7 (21.9%)/12 (37.5%)/11 (34.4%)/2 (6.3%)
   Number of patients with salvage surgery prior to HSFRT   7 (21.9%)
   Number of patients with chemotherapy prior to HSFRT      18 (56.25%)
  Recurrent tumor at time of HSFRT                          
   Median time from initial irradiation (years)             1.9 \[0.08-13.2\]
   Number of lesions                                        34
   Median tumor volume (cm^3^)                              6.1 \[0.1-42.2\]
  HSFRT characteristics                                     N = 34
   Dose: 27 Gy / 30 Gy                                      2 (5.9%)/32 (94.1%)
   Number of fractions: 3 / 6                               2 (5.9%)/32 (94.1%)
   Dose per fraction: 9 Gy / 5 Gy                           2 (5.9%)/32 (94.1%)
   Isodose: 80%                                             34 (100%)
   PTV margins: 2 mm/3 mm/5 mm                              18 (52.9%)/15 (44.1%)/1 (2.9%)
   Concomitant drug: bevacizumab                            1 (2.9%)
  --------------------------------------------------------- ------------------------------------------

Abbreviations: ECOG, Eastern Cooperative Oncology Group; HFSRT, hypofractionated stereotactic radiotherapy; PTV, planning target volume; RPA, recursive partitioning analysis.

The majority of recurrences (23; 67.7%) were localized within the initial PTV, 2 (5.9%) were localized outside and 1 (2.9%) was on the periphery (defined as 1 cm on either side of the initial PTV boundaries). For 8 (23.5%), the relationship with the initial PTV was unknown (initial dosimetric data were lost when computer versions were updated).

HFSRT Characteristics {#section13-1533033818806498}
---------------------

The median tumor volume was of 6.1 (0.1-42.2) cm^3^, the PTV was 15 (0.6-67.5) cm^3^, and the prescription volume (isodose line 80%) was 19.1 (1.4-66.6) cm^3^. The median maximum dose (Dmax), median minimum dose (Dmin), and median mean dose (Dmean) were 38.7 (32.7-42.0), 29.1 (14.0-32.4), and 35.1 (31.5-37.5) Gy, respectively.

Most patients (24; 75%) were subsequently treated with various agents such as TMZ, bevacizumab, fotemustine, lomustine, PCV, erlotinib, afatinib, or C-MET inhibitor after the HFSRT and/or at the new recurrence.

At the time of analysis, no patients had undergone another surgery following the HFSRT.

Survival {#section14-1533033818806498}
--------

The median follow-up was 20.9 (2.8-47.4) months. At the time of the analysis, 20 patients (62.5%) had died.

### OS following HFSRT {#section15-1533033818806498}

Median OS calculated from the reirradiation was 15.6 (8.2-17.3) months. The survival rate at 6 and 12 months was 83.4% and 64.6%, respectively. Median OS for patients with GBM was 8.2 (5.7-17.3) months and that for patients with grade III glioma was 19.5 (12.6-24) months ([Figure 1](#fig1-1533033818806498){ref-type="fig"}).

![Kaplan-Meier OS after HFSRT for patients with GBM and grade III glioma. OS indicates overall survival; HFSRT, hypofractionated stereotactic radiotherapy; GBM, glioblastoma.](10.1177_1533033818806498-fig1){#fig1-1533033818806498}

In univariate analysis, the initial irradiation technique, the initial T2 FLAIR volume, concomitant bevacizumab with the primary irradiation, reirradiation tumor volumes, and reirradiation mean dose were significant prognostic factors (*P* \< .05) of OS ([Table 3](#table3-1533033818806498){ref-type="table"}). In multivariate analysis, tumor grade III (*P* = .0027), a mean dose \>35 Gy (*P* = .0055), and an ECOG status \<2 at the time of reirradiation (*P* = .0023) significantly improved OS ([Table 3](#table3-1533033818806498){ref-type="table"}).

###### 

Univariate and Multivariate Analysis: Prognostic Factors for OS.

![](10.1177_1533033818806498-table3)

                                                                 HR      95% CI         *P* Value
  -------------------------------------------------------------- ------- -------------- -----------
  Univariate analysis for OS following HSFRT                                            
   Initial irradiation technique: IMRT vs 3D                     0.227   0.056-0.926    .0388
   Initial T2 FLAIR volume: \>100 vs ≤100 cm^3^                  4.147   1.085-15.856   .0376
   Initial irradiation with concomitant bevacizumab: yes vs no   4.853   1.505-15.649   .0082
   HSFRT GTV volume: \>6 vs ≤6 cm^3^                             5.185   1.691-15.900   .0040
   HSFRT PTV volume: \>15 vs ≤15 cm^3^                           3.281   1.169-9.208    .0240
   Prescription volume (isodose line 80%): \>19 vs ≤19 cm^3^     3.281   1.169-9.208    .0240
  Multivariate analysis for OS following HSFRT                                          
    Tumor grade: grade IV vs grade III                           6.234   1.887-20.591   .0027
    Stereotactic mean dose: \>35 Gy vs ≤35 Gy                    0.219   0.075-0.639    .0055
    ECOG status: 2 vs 0-1                                        8.115   2.108-31.240   .0023

Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume; HR, hazard ratio; HFSRT, hypofractionated stereotactic radiotherapy; IMRT, intensity-modulated radiation therapy; PTV, planning target volume; OS, overall survival.

### Progression-free survival {#section16-1533033818806498}

The PFS after HFSRT was 3.7 (3-5.7) months overall: 3.6 (2.4-5.6) months for patients with GBM and 4.5 (2.9-8.9) months for patients with grade III glioma ([Figure 2](#fig2-1533033818806498){ref-type="fig"}).

![Kaplan-Meier PFS after HFSRT for patients with GBM and grade III glioma. PFS indicates progression-free survival; HFSRT, hypofractionated stereotactic radiotherapy; GBM, glioblastoma.](10.1177_1533033818806498-fig2){#fig2-1533033818806498}

The median time to the first MRI evaluation after HSFRT was 3 (1-10) months.

The first progression after HFSRT based on MRI evaluation was located inside the PTV for 25 patients (44%). It was outside the PTV in 36%, and both inside and outside in 20%.

The maximum reirradiation dose above 38 Gy was a significant prognostic factor of PFS (*P =* .0179) in multivariate analysis ([Table 4](#table4-1533033818806498){ref-type="table"}).

###### 

Univariate and Multivariate Analysis: Prognostic Factors for PFS.

![](10.1177_1533033818806498-table4)

                                                  HR      95% CI        *P* Value
  ----------------------------------------------- ------- ------------- -----------
  Univariate analysis for PFS                                           
   Maximum dose: \>38 Gy vs ≤38 Gy                0.74    0.146-0.958   .0405
  Multivariate analysis for PFS                                         
   Stereotactic maximum dose: \>38 Gy vs ≤38 Gy   0.317   0.122-0.820   .0179

Abbreviations: CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.

Toxicity {#section17-1533033818806498}
--------

Treatment was completed in all patients in the specified time. All patients were included in the analysis. One patient was lost to follow-up at the end of the HFSRT. Treatment was well tolerated, no acute toxicity \>grade 2 was observed, and the neurological deteriorations correlated with neoplastic progression during the follow-up. Nevertheless, one patient presented homonymous hemianopsia during the HFSRT, but this resolved during the follow-up. Ten patients (31.25%) had suspected radionecrosis. If in doubt between radionecrosis or progression, a new MRI at 2 months or a multimodal MRI has been proposed. In 6 patients, this suspicion corresponded to tumor progression. For the other patients, radionecrosis was suggested on multimodal MRI. These patients had asymptomatic radionecrosis at the time of diagnosis.

Discussion {#section18-1533033818806498}
==========

The standard of care for patients with recurrent GBM or grade III glioma has not yet been clearly defined, and many approaches are available for salvage strategies, including surgery, reirradiation, or systemic agents.^[@bibr10-1533033818806498][@bibr11-1533033818806498][@bibr12-1533033818806498][@bibr13-1533033818806498][@bibr14-1533033818806498][@bibr15-1533033818806498][@bibr16-1533033818806498][@bibr17-1533033818806498]-[@bibr18-1533033818806498]^

In the current study, we evaluated the feasibility of HFSRT as a salvage treatment for HGG. Our patients were long survivors, as the median time between HGG diagnosis and the first relapse and the time between the initial radiotherapy and HFSRT were 1.3 and 1.9 years, respectively. This can be explained by the large proportion of patients with grade III glioma (43.75%). In addition, 7 patients presented a transformation from low-grade glioma to HGG with a slow disease evolution. Furthermore, most patients had experienced several relapses between the initial radiation therapy and the HFSRT (median number: 2), and management was often multimodal with different treatments (new surgery, chemotherapy).

Fogh *et al* ^[@bibr35-1533033818806498]^ reported that patients with early relapse from initial irradiation (\<6 months) had a more unfavorable prognosis, suggesting they should not qualify for salvage therapy.

The HFSRT appeared to be a feasible and a short minimally invasive approach for the treatment of HGG recurrence in eloquent and/or previously irradiated areas. Indeed, this is particularly important because relapse of HGG principally occurs within the 2 cm around the initial tumor site.^[@bibr17-1533033818806498],[@bibr47-1533033818806498]^

In our study, treatment was well tolerated and did not block the possibility of further treatments, as most patients were treated with various agents after HFSRT. These results suggest that this technique is safe.

In the literature, many authors have studied hypofractionated or moderately fractionated stereotactic radiotherapy delivered with a linear accelerator for the management of HGG recurrence and also concluded that HFSRT reirradiation for HGG recurrence is feasible with minimal adverse effects^[@bibr19-1533033818806498][@bibr20-1533033818806498][@bibr21-1533033818806498][@bibr22-1533033818806498][@bibr23-1533033818806498][@bibr24-1533033818806498][@bibr25-1533033818806498][@bibr26-1533033818806498][@bibr27-1533033818806498][@bibr28-1533033818806498][@bibr29-1533033818806498][@bibr30-1533033818806498][@bibr31-1533033818806498][@bibr32-1533033818806498][@bibr33-1533033818806498][@bibr34-1533033818806498][@bibr35-1533033818806498][@bibr36-1533033818806498][@bibr37-1533033818806498][@bibr38-1533033818806498][@bibr39-1533033818806498][@bibr40-1533033818806498][@bibr41-1533033818806498][@bibr42-1533033818806498][@bibr43-1533033818806498]-[@bibr44-1533033818806498],[@bibr46-1533033818806498]^ (details of these studies are summarized in [Table 5](#table5-1533033818806498){ref-type="table"}. The studies with Gamma Knife or CyberKnife as well single-fraction radiosurgery studies were not included).

###### 

Review of the Literature Including HFSRT With LINAC for Reirradiation of Recurrent HGG With or Without Chemotherapy.

![](10.1177_1533033818806498-table5)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors and Year                                         Number of Patients   Median Age         GBM/Grade III   Median KPS   Total Dose; Dose per Fraction (Gy)   Number of Fractions; Number of fr per Week   PTV Margins (mm)   IDS         Median Tumor Volume (cm^3^)   Median Time Between Initial Irradiation and HFSRT (Months)   Surgery Before HFSRT   Associated Chemotherapy      OS (Months)             PFS (Months)      Prognostic Factors                              Complications
  -------------------------------------------------------- -------------------- ------------------ --------------- ------------ ------------------------------------ -------------------------------------------- ------------------ ----------- ----------------------------- ------------------------------------------------------------ ---------------------- ---------------------------- ----------------------- ----------------- ----------------------------------------------- ---------------------------------------
  Laing *et al* 1993^[@bibr19-1533033818806498]^           22                   34 (14-56)         12/7            70           20-50; 5                             5; daily                                     2                  80-90       25 (1-93)                     20                                                           6                      --                           9.8                     --                --                                              Neurological deterioration: 5

  Glass *et al* 1997^[@bibr20-1533033818806498]^           20                   44 (6-73)          13/7            90           42; 6                                7; 2                                         --                 70          14 (2-122)                    8                                                            --                     CDDP                         13.7                    4.6               --                                              Radionecrosis: 3

  Shepherd *et al* 1997^[@bibr21-1533033818806498]^        33                   37 (19-55)         0/36            80           20-50; 5                             4-10; daily                                  2                  80-90       24 (3-93)                     29                                                           --                     --                           11                      --                --                                              Radionecrosis: 6\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Reoperation: 2

  Hudes *et al* 1999^[@bibr22-1533033818806498]^           20                   52 (26-77)         19/1            80           24-35; 3-3.5                         8-10; daily                                  0                  80-95       12.6 (0.9-47.5)               3.1                                                          --                     --                           10.5                    --                --                                              --

  Lederman *et al* 2000^[@bibr23-1533033818806498]^        88                   56 (21-82)         88/0            70           24; 6                                4; 1                                         --                 80-90       32.7 (1.5-150)                7.8                                                          --                     Paclitaxel                   7                       --                Tumor volume                                    Radionecrosis: 7\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Reoperation: 11

  Selch *et al* 2000^[@bibr24-1533033818806498]^           21                   54 (14-72)         14/7            80           20-35; 4-6                           5; --                                        0-3                70-90       11.6 (4.5-33.7)               11                                                           21%                    --                           6                       4                 --                                              --

  Voynov *et al* 2002^[@bibr25-1533033818806498]^          10                   48 (33-85)         4/6             80           25-40; 5                             5-8; --                                      0                  71-93       34.7 (4.3-75)                 19                                                           5                      --                           10.1                    --                --                                              Reoperation: 2

  Vodermark *et al* 2005^[@bibr26-1533033818806498]^       19                   50 (11-74)         9/10            90           20-30; 4-10                          2-6; --                                      1-3                70-90       15 (4-70)                     19                                                           12                     --                           9.3                     4.9               Tumor grade                                     Reoperation: 5

  Grosu *et al* 2005^[@bibr27-1533033818806498]^           44                   50 (36-75)         33/11           75           30; 5                                6; daily                                     3                  100         15 (1-61)                     16                                                           --                     TMZ                          13                      --                SPECT/CT/MRI, TMZ                               --

  Wurm *et al* 2006^[@bibr28-1533033818806498]^            25                   46 (11-66          20/5            80           25-30; 5                             5-6; daily                                   --                 80          16.5 (1-70.9)                 --                                                           --                     Topotecan                    14.5                    10.5              --                                              --

  Ernst-Stecken *et al* 2007^[@bibr29-1533033818806498]^   15                   49 (31-69)         11/4            80           35; 7                                5; 3                                         3                  90          5.7 (0.8-22)                  10                                                           --                     --                           12                      7                 --                                              --

  Schwer *et al* 2008^[@bibr30-1533033818806498]^          15                   47 (23-65)         11/4            70           18-36; 6-12                          3; 3                                         2                  90          41.3 (5-150)                  12                                                           7                      Gefitinib                    10                      7                 --                                              --

  Fokas *et al* 2009^[@bibr31-1533033818806498]^           53                   53 (22-71)         53/0            --           25-60; 2-5                           5-30; --                                     3                  90          35.01 (3-204)                 --                                                           23                     --                           9                       12                KPS                                             --

  Patel *et al* 2009^[@bibr32-1533033818806498]^           10                   44 (28-60)         10/0            90           36; 6                                6; 2                                         0                  90          51.1 (16.1-123.3)             14.9                                                         7                      --                           7.5                     --                Radiographic responders                         --

  Gutin *et al* 2009^[@bibr33-1533033818806498]^           25                   56 (30-80)         20/5            80           30; 6                                5; --                                        5                  100         34 (2-62)                     15                                                           --                     Bevacizumab                  GBM: 12.5\              GBM: 7.3\         --                                              Reoperation: 3\
                                                                                                                                                                                                                                                                                                                                                                                                Grade III: 16.5         Grade III: 7.5                                                    Hemorrhage: 1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Wound dehiscence: 1

  Henke *et al* 2009^[@bibr34-1533033818806498]^           31                   50 (16-74)         29/2            90           20-25; 4-5                           4-5; --                                      3-10               --          --                            18                                                           15                     --                           10.2                    --                --                                              --

  Fogh *et al* 2010^[@bibr35-1533033818806498]^            147                  53 (28-80)         105/42          --           35; 3.5                              10; daily                                    --                 85-90       22 (0.6-104)                  8                                                            84                     Various agents               GBM: 8\                 --                Younger age\                                    Steroids increase: 19
                                                                                                                                                                                                                                                                                                                                                                                                Grade III: 11                             Smaller GTV\                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                          Shorter time between diagnosis and recurrence   

  Minniti *et al* 2013^[@bibr36-1533033818806498]^         54                   52 (30-72)         38/16           80           30; 6                                5; daily                                     3-5                90          9.7 (3.1-32.3)                15.5                                                         12                     TMZ                          12.4                    6                 KPS\                                            Neurological deterioration grade 3: 4
                                                                                                                                                                                                                                                                                                                                                                                                                                          Tumor grade                                     

  Shapiro *et al* 2013^[@bibr37-1533033818806498]^         24                   56 (30-80)         20/4            80           30; 6                                5; 2                                         5                  --          --                            --                                                           2                      Bevacizumab                  32.1 (from diagnosis)   7.5               Radiographicresponse                            --

  Ogura *et al* 2013^[@bibr38-1533033818806498]^           30                   52.5 (19-81)       15/9            --           22.5-35; 4.5-7                       5; daily                                     1-2                70-80       3.02 (0-36.1)                 24.8                                                         --                     Various agents               10.4                    3                 Morphology\                                     Radionecrosis grade 3: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                          Tumor type\                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                          Tumor volume                                    

  Ciammela *et al* 2013^[@bibr39-1533033818806498]^        15                   51.5 (41-73)       91/0            90           25; 5                                5; daily                                     3--5               70          --                            10.8                                                         --                     --                           9.5                     --                Age\                                            Neurological deterioration: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                          Initial extent surgery\                         
                                                                                                                                                                                                                                                                                                                                                                                                                                          RPA\                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                          KPS\                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                          MGMT status                                     

  Wuthrick *et al* 2014^[@bibr40-1533033818806498]^        11                   51 (37-67)         8/3             --           30-42; 2.5-3.75                      10-15; daily                                 0                  85-90       16.75 (0.05-72.01)            19.5                                                         --                     Sunitinib                    11                      5.8               --                                              --

  Miwa *et al* 2014^[@bibr41-1533033818806498]^            21                   53.9 (22-76)       21/0            80           25-35; 5-7                           5; daily                                     3                  80-95       --                            12                                                           --                     TMZ                          11                      6                 KPS                                             Radionecrosis: 2

  Dincoglan *et al* 2015^[@bibr42-1533033818806498]^       28                   55.6 (38-76)       28/0            80           25; 5                                5; daily                                     3                  85-95       --                            11.2                                                         --                     --                           10.3                    5.8               KPS\                                            --
                                                                                                                                                                                                                                                                                                                                                                                                                                          Age\                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                          PTV size\                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                          Time from diagnosis to recurrence               

  Minniti *et al* 2015^[@bibr43-1533033818806498]^         54                   54 (30-72)         42/12           70           25; 5                                5; daily                                     1--2               90          12.4 (1.8-43.3)               14                                                           --                     Bevacizumab or fotemustine   Bevacizumab: 11\        Bevacizumab: 6\   KPS\                                            Radionecrosis: 3
                                                                                                                                                                                                                                                                                                                                                                                                Fotemustine: 8.3        Fotemustine: 4    Tumor grade\                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                          Bevacizumab                                     

  Shi *et al* 2016^[@bibr44-1533033818806498]^             12                   46 (33-66)         8/4             80           30-35; 3-3.5                         10; daily                                    5                  --          26.8 (2.7-143)                --                                                           --                     Panobinostat 10-20-30 mg     7.8, 6.1, 16.1          --                --                                              Radionecrosis grade 3: 1

  Antoni *et al* 2016^[@bibr45-1533033818806498]^          20                   55.7 (33.9-82.9)   13/7            --           18.75-37.5; 6.25                     3-6; 3                                       --                 Isocenter   0.91 (0.02-18.5)              18.3                                                         --                     TMZ\                         17.7                    12                Bevacizumab\                                    --
                                                                                                                                                                                                                                                                                                                                                                   Bevacizumab                                                            High-dose radiation                             

  Clarke *et al* 2017^[@bibr46-1533033818806498]^          15                   63 (50-73)         10/5            90           27-33; 9-11                          3; --                                        2-5                --          --                            --                                                           --                     Bevacizumab                  13                      7                 --                                              Radionecrosis grade 3: 1

  Present study                                            32                   61.5 (33-77)       18/14           --           27-30; 5-9                           3-6; 2-3                                     2-5                80          6.1 (0.1-42.2)                22.8                                                         7                      --                           15.6                    3.7               ECOG status\                                    Radionecrosis grade 1: 4
                                                                                                                                                                                                                                                                                                                                                                                                                                          Tumor grade\                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                          Dose                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CT, computed tomography, fr, fraction; GBM, glioblastoma; GTV, gross tumor volume; HFSRT, hypofractionated stereotactic radiotherapy; IDS, isodose surface; KPS, Karnofsky performance score; MGMT, O^6^-methylguanin-DNA-methyltransferase; MRI, magnetic resonance imaging; OS, overall survival; PFS, progression-free survival; PTV, planning target volume; RPA, recursive partitioning analysis of prognostic factors; SPECT, single-photon emission computed tomography; TMZ, temozolomide.

In this current study, HFSRT was delivered without chemotherapy, except for one patient, who was treated with concomitant bevacizumab. In 1997, Glass *et al* ^[@bibr20-1533033818806498]^ tested this combined approach of stereotactic radiotherapy and chemotherapy with cisplatin. Since then, several studies that combined HFSRT with various drugs (paclitaxel, TMZ, topotecan, gefitinib, sunitinib, fotemustine, panobinostat, or bevacizumab)^[@bibr20-1533033818806498],[@bibr23-1533033818806498],[@bibr27-1533033818806498],[@bibr28-1533033818806498],[@bibr30-1533033818806498],[@bibr33-1533033818806498],[@bibr35-1533033818806498][@bibr36-1533033818806498][@bibr37-1533033818806498]-[@bibr38-1533033818806498],[@bibr40-1533033818806498],[@bibr41-1533033818806498],[@bibr43-1533033818806498][@bibr44-1533033818806498][@bibr45-1533033818806498]-[@bibr46-1533033818806498]^ have been conducted. According to these studies, combined modality management appears to be feasible and well tolerated, and the results are encouraging especially with bevacizumab.^[@bibr33-1533033818806498],[@bibr37-1533033818806498],[@bibr43-1533033818806498],[@bibr45-1533033818806498],[@bibr46-1533033818806498]^ The RTOG 1205 randomized phase II trial could shed new light on the efficacy of this strategy and clarify the role of bevacizumab in the management of HGG recurrence.

In the literature, hypofractionated stereotactic regimens varied from one study to another and sometimes within the same study. The reported doses ranged from 18 to 50 Gy with different rules for prescription, fractionations, and staggering. As a result, it is difficult to compare the radiobiological effects of these regimens. To date, no phase III trials have been conducted to compare the different stereotactic regimens and the vast majority of studies have been retrospective. Thus, no scheme has shown a benefit with respect to others.

In our study, the main scheme used was 30 Gy in 6 fractions of 5 Gy, the treatment plans were normalized to 100% at the isocenter and prescribed to the 80% isodose line. Also, the dose was delivered with a variable dose distribution: Dmax, Dmin, and Dmean were ranged from 32.7 to 42.0, 14.0 to 32.4, and 31.5 to 37.5 Gy, respectively. For our HSFRT scheme, a Dmean \>35 Gy appeared to significantly prolong OS and Dmax \>38 Gy significantly prolonged PFS. These results suggested that the dose distribution had a positive impact on tumor control and therefore that dose escalation might be beneficial.

A trend toward a beneficial effect on survival was suggested by Vordermark *et al*.^[@bibr26-1533033818806498]^ In a study of 19 patients treated for HGG recurrence with a dose of 20 to 30 Gy in different fractionations (2-6 fractions), prescribed to a median isodose of 80%, OS was better for dose over 30 Gy.

Fogh *et al* ^[@bibr35-1533033818806498]^ suggested the benefit of a dose over 35 Gy. In a study of 147 patients treated for HGG relapse by HFSRT at a median dose of 35 Gy in daily fractions of 3.5 Gy, prescribed for an isodose of 85% to 90%, survival seemed to be increased (*P* = .07). However, Laing *et al* ^[@bibr19-1533033818806498]^ and Shepherd *et al* ^[@bibr21-1533033818806498]^ reported that a dose \>40 Gy was a major predictor of toxicity (especially major consumption of corticosteroids) in patients treated with doses of 20 to 50 Gy in 5 fractions (prescription: isodose 80% or 90%), thus highlighting the small therapeutic windows.

Recently, Clarke *et al* ^[@bibr46-1533033818806498]^ evaluated a dose-escalation strategy for the management of recurrent HGG treated with HFSRT in a phase I study. Their scheme was based on a previous study (Gutin *et al* ^[@bibr33-1533033818806498]^), which reported the feasibility of HFSRT with a scheme of 30 Gy in 5 fractions, prescribed to the 100% isodose line. The dose-escalation study evaluated tolerance of 3 dose steps: 3 × 9 Gy, 3 × 10 Gy, and 3 × 11 Gy in combination with bevacizumab. The results attested the feasibility of the strategy at doses up to 33 Gy in 3 fractions.

In the literature, the reported OS is in the range of 6 (Selche *et al* ^[@bibr24-1533033818806498]^) to 17.7 months (Antoni *et al* ^[@bibr45-1533033818806498]^), and PFS ranged from 3 (Ogura *et al* ^[@bibr38-1533033818806498]^) to 12 months (Fokas *et al* ^[@bibr31-1533033818806498]^, Antoni *et al* ^[@bibr45-1533033818806498]^). In our data, OS was 15.6 months; this good result could have been explicated by the high proportion (43.75%) of patients treated for grade III glioma. Our results suggest that grade III glioma was a significant prognostic factor for longer OS; the specific OS for grade III glioma was 19.5 months versus 8.2 months for GBM. Indeed, these different pathologies have different courses and prognoses; survival was better in patients with grade III gliomas especially since these gliomas develop from low-grade gliomas.

Equally, a high proportion (71.9%) of patients had gross or subtotal initial surgery, which may have had an impact on patient survival.^[@bibr48-1533033818806498]^

Although our patient population was in keeping with populations in the literature with respect to the characteristics of patients, tumor recurrences, and the stereotactic technique, PFS in our study was low.

The first progressions suspected on MRI after HFSRT were inside the PTV for majority of patients. Niyazi *et al* ^[@bibr49-1533033818806498]^ reported a similar recurrence pattern after fractionated reirradiation with bevacizumab in a study of 31 patients treated for recurrent HGG. Altogether, 61.3% of progressions were in-field and 38.7% at the margin or ex-field. Similarly, Shapiro *et al* ^[@bibr37-1533033818806498]^ used a reirradiation regimen of 30 Gy in 5 fractions with concomitant bevacizumab to treat 24 patients with HGG relapse and studied recurrence patterns: 52.4% progressions were in field, 23.8% were marginal, and 23.8% were outside the field.

Actually, it is quite challenging to interpret radiological evaluation imaging after stereotactic radiotherapy because it is difficult to distinguish between progression, pseudoprogression, and radionecrosis. Thus, the short PFS could be explained by an overestimation of progression and an underestimation of radionecrosis.

Furthermore, it would be interesting to evaluate the effect of cumulative BED and the time between irradiations on the occurrence of radionecrosis. However, due to the small number of events and the limited number of patients, a relevant statistical analysis is not feasible.

The limitations of this study were its retrospective design, selection bias, and of various treatment factors, including surgery and chemotherapy before and after HFSRT. In addition, molecular biology information was only available for a minority of patients and specific statistical analyses were not available. However, our data were similar to those in the literature especially for the sample size.

Conclusion {#section19-1533033818806498}
==========

The HFSRT appears to be a feasible and effective salvage treatment option for recurrent grade III glioma or GBM, with OS of 15.6 months. Prognostic factors associated with longer OS were a good general state of health and grade III glioma. Dosimetric data suggested that the dose distribution had an impact on tumor control and indicate that a study with dose-escalation is warranted. These results need to be confirmed in a prospective study with a greater number of patients.
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BED

:   biologically effective dose

CI

:   confidence interval

CTV

:   clinical target volume

CT

:   computed tomography

Dmax

:   maximum dose

Dmean

:   mean dose

Dmin

:   minimum dose

GBM

:   glioblastoma

ECOG

:   Eastern Cooperative Oncology Group

HFSRT

:   hypofractionated stereotactic radiotherapy

HGG

:   high-grade glioma

MRI

:   magnetic resonance imaging

PCV

:   lomustine, procarbazine and vincristine

PFS

:   progression-free survival

PTV

:   planning target volume

OS

:   overall survival

TMZ

:   temozolomide.
